Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 36 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

7%

1 of 15 completed trials have results

Key Signals

7 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
30(83.3%)
Phase 2
3(8.3%)
N/A
2(5.6%)
Early Phase 1
1(2.8%)
36Total
Phase 1(30)
Phase 2(3)
N/A(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT07444281Phase 1Recruiting

An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

Role: lead

NCT04316624Phase 1Completed

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Role: collaborator

NCT07341828Phase 1Not Yet Recruiting

A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

Role: collaborator

NCT07344311Phase 1Recruiting

A Phase I Trial of A-CAR032 in Participants With mCRPC

Role: lead

NCT06590246Phase 1Recruiting

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

Role: lead

NCT05800977Phase 1Recruiting

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Role: lead

NCT05632380Phase 1Recruiting

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Role: collaborator

NCT07198867Phase 1Recruiting

A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT04696432Phase 1Completed

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Role: collaborator

NCT04655677Phase 1Completed

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Role: collaborator

NCT04317885Phase 1Completed

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Role: collaborator

NCT04602104Phase 1Completed

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS

Role: collaborator

NCT04544215Phase 1Suspended

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

Role: collaborator

NCT04036019Phase 1Completed

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Role: collaborator

NCT04693676Phase 1Unknown

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Role: collaborator

NCT04208646Phase 2Completed

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Role: lead

NCT05521802Phase 1Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT05475847Phase 1Unknown

Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer

Role: collaborator

NCT04313647Phase 1Completed

A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Role: collaborator

NCT04388982Phase 1Unknown

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease

Role: collaborator